149709-58-0

Basic information

• Product Name: ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester
• Synonyms: ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester;(R)-tert-butyl (1-([1,1'-biphenyl]-4-yl)-3-oxopropan-2-yl)carbamate;[(1R)-2-(Biphenyl-4-yl)-1-formylethyl]carbamic acid tert-butyl ester;((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl este
• CAS NO: 149709-58-0
• Molecular Formula: C₂₀H₂₃NO₃
• Molecular Weight: 325.40152
• EINECS: -0
• Product Categories: LCZ696
• Mol File: 149709-58-0.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 475.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.097±0.06 g/cm3(Predicted)
• PKA: 11.17±0.46(Predicted)
• CAS DataBase Reference: ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester(149709-58-0)
• EPA Substance Registry System: ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester(149709-58-0)

Safety Data

• Hazardous Substances Data: 149709-58-0(Hazardous Substances Data)

Usage

Uses

tert-?Butyl (R)?-?(1-?([1,?1''-Biphenyl]?-?4-?yl)?-?3-?oxopropan-?2-?yl)?carbamate is an impurity of LCZ696 (L270005), a novel dual-acting inhibitor of angiotensin II receptor and neprilysin, which can be used for blood pressure reduction.

Upstream product

• 1213855-60-7 methyl (R)-3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 1426129-50-1 N-[(1R)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 62561-75-5 (R)-2-amino-3-(4-iodophenyl)propanoic acid 
• 673-06-3 D-(R)-phenylalanine 
• 1383027-39-1 C₁₇H₂₃F₃N₂O₇S 
• 929872-80-0 tert-butyl (R)-3-(4-hydroxyphenyl)-1-[methoxy(methyl)amino]-1-oxopropan-2-ylcarbamate 
• 70642-86-3 N-(tert-butoxycarbonyl)-D-tyrosine 
• 149709-56-8 methyl N-(tert-butoxycarbonyl)-O-[(trifluoromethyl)sulfonyl]-D-tyrosinate 
• 149818-98-4 methyl (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino><1,1'-biphenyl>-4-propanoate 
• 128779-47-5 (2R)-3-(biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 162972-36-3 (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino>-N-methoxy-N-metyl<1,1'-biphenyl>-4-propanamide 
• 76757-90-9 N-(tert-butoxycarbonyl)-D-tyrosine methyl ester 

Downstream Products

• 149709-59-1 (R)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpent-2-enoic acid ethyl ester 
• 752174-62-2 (2R,4S)-4-amino-5-biphenyl-4-yl-2-methylpentanoic acid ethyl ester 
• 1012341-48-8 (2E,4R)-5-{[1,1'-biphenyl]-4-yl}-4-{[(tert-butoxy)carbonyl]amino}-2-methylpent-2-enoic acid 
• 1012341-50-2 (2R,4S)-5-[(1,1‘-biphenyl)-4-yl]-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid 
• 149690-12-0 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid ethyl ester hydrochloride 
• 149709-60-4 ethyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoate 
• 149709-59-1 ethyl 5-(4-<1,1'-biphenyl>yl)-4-<<(1,1-dimethylethoxy)carbonyl>amino>-2-methyl-2-pentenoate 
• 149709-62-6 α-ethyl (αR,γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 149709-63-7 α-ethyl (αS,γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 149709-63-7 α-ethyl (γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 753421-85-1 ethyl (γS)-γ-amino-α-methyl<1,1'-biphenyl>-4-pentanoate 

Relevant articles and documents

Synthesis method of sacubitril drug intermediate

The invention relates to the technical field of synthesis of medical intermediates, in particular to a synthesis method of a sacubitril drug intermediate. The synthesis method comprises the followingsynthesis route: under the protection of nitrogen, adding a compound II and a solvent into a reaction flask, stirring to dissolve, adding diisobutylaluminum hydride according to the feeding molar ratio of compound II to diisobutylaluminum hydride (DIBAH) of 1: (1-2), and controlling the temperature, stirring for reaction, and monitoring the reaction by TLC; after the reaction is finished, adding aKHSO4/water solution for quenching reaction; combining the obtained solution with a 1N HCl solution, stirring for 5 minutes, and separating an organic phase; extracting the aqueous phase with EtOAc,combining the organic phases, drying with anhydrous sodium sulfate, and concentrating to dryness to obtain a compound I; according to the invention, diisobutylaluminum hydride is selected to replace lithium aluminum hydride which is easy to explosively decompose when encountering water. The method is simple in reaction operation, high in yield and suitable for industrial large-scale production.

Preparation method for gamma-aminovalerate derivatives

The invention discloses a preparation method for gamma-aminovalerate derivatives. The method comprises the steps of reduction, oxidization, Wittig reaction and hydrogenation reduction with a starting material of N-((tert-butoxycarbonyl)amino-4,4-biphenyl-R-propanoate. The method has the advantages that the process route is short; chiral impurities are reduced by fixing a chiral center in the raw material; oxidized impurities are prevented from being generated by protecting the primary amine; and by using a palladium-charcoal or ruthenium catalyst for assisting a ligand to reduce ethylenic bond, the chiral selectivity is high, the yield is high and the method is suitable for large-scale industrial production.

Preparation method of sacubitril intermediate having low triphenylphosphine oxide content

The invention relates to a preparation method of a sacubitril intermediate having low triphenylphosphine oxide content. The preparation method comprises that water, isopropyl acetate, sodium bromide, sodium bicarbonate and tetramethylpiperidine oxide into (R)-tert-butyl(1-([1, 1'-biphenyl]-4-yl)-3-hydroxypropane-2-yl)carbamate, adding a sodium hypochlorite solution into the mixture drop by drop for a reaction, after the reaction, carrying out layering, taking an organic layer, adding ethoxyformylethylidenetriphenyl phosphorane into the organic layer, after a reaction, concentrating the reaction product, removing isopropyl acetate, adding ethanol, water and lithium hydroxide into the mixture, carrying out heating until reflux, carrying out concentration until drying, adding water and activated carclazyte into the product, carrying out stirring at the room temperature, filtering the mixture, adding ethanol and acetic acid into the filtrate, carrying out heating until reflux, and carrying out cooling and stirring to precipitate solids which are the sacubitril intermediate finished products. The preparation method can reduce triphenylphosphine oxide content of the (R)-tert-butyl(1-([1, 1'-biphenyl]-4-yl)-3-hydroxypropane-2-yl)carbamate.